Press Releases Check out the latest news from Tavanta July 12, 2021 Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer August 31, 2020 Tavanta Therapeutics, a New Specialty Pharmaceutical Company, Has Diverse Pipeline of Novel Drugs and Risk-balanced Approach to Product Development October 29, 2019 DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT-45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer October 21, 2019 Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and New President of DRGT Research September 18, 2019 DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99) July 15, 2019 DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure June 10, 2019 DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor 123>>
